These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 476567

  • 1. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3).
    Vosika GJ, Schmidtke JR, Goldman A, Ribi E, Parker R, Gray GR.
    Cancer; 1979 Aug; 44(2):495-503. PubMed ID: 476567
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of intravenous mycobacterial cell wall skeleton and trehalose dimycolate attached to oil droplets.
    Vosika G, Giddings C, Gray GR.
    J Biol Response Mod; 1984 Dec; 3(6):620-6. PubMed ID: 6512562
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of iv mycobacterial cell wall skeleton and cell wall skeleton combined with trehalose dimycolate.
    Vosika GJ, Gray GR.
    Cancer Treat Rep; 1983 Sep; 67(9):785-90. PubMed ID: 6883355
    [Abstract] [Full Text] [Related]

  • 4. Clinical immunotherapy trials of bacterial components derived from Mycobacteria and Nocardia.
    Vosika GJ.
    J Biol Response Mod; 1983 Sep; 2(4):321-42. PubMed ID: 6358421
    [Abstract] [Full Text] [Related]

  • 5. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
    Yamamura Y, Yoshizaki K, Azuma I, Yagura T, Watanabe T.
    Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
    [Abstract] [Full Text] [Related]

  • 6. Clinical Phase I investigation of intravenous oil attached mycobacterial components as immunotherapeutic agents.
    Vosika G, Trenbeath T, Giddings C, Gray GR.
    Adv Exp Med Biol; 1983 Aug; 166():159-69. PubMed ID: 6650279
    [Abstract] [Full Text] [Related]

  • 7. Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration.
    Yarkoni E, Meltzer MS, Rapp HJ.
    Int J Cancer; 1977 Jun 15; 19(6):818-21. PubMed ID: 326683
    [Abstract] [Full Text] [Related]

  • 8. Trehalose dimycolate from various mycobacterial species induces differing anti-infectious activities in combination with muramyl dipeptide.
    Masihi KN, Brehmer W, Lange W, Werner H, Ribi E.
    Infect Immun; 1985 Dec 15; 50(3):938-40. PubMed ID: 4066040
    [Abstract] [Full Text] [Related]

  • 9. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, Prehn RT.
    Cancer; 1976 Feb 15; 37(2):684-92. PubMed ID: 766947
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets.
    Gray GR, Ribi E, Granger D, Parker R, Azuma I, Yamamoto K.
    J Natl Cancer Inst; 1975 Sep 15; 55(3):727-30. PubMed ID: 1159851
    [Abstract] [Full Text] [Related]

  • 11. Intratumor chemoimmunotherapy with mitomycin C and components from mycobacteria in regression of line 10 tumors in guinea pigs.
    McLaughlin CA, Cantrell JL, Ribi E, Goldberg EP.
    Cancer Res; 1978 May 15; 38(5):1311-6. PubMed ID: 205361
    [Abstract] [Full Text] [Related]

  • 12. Intralesional BCG application in malignant melanoma.
    Sopková B, Kolár V.
    Neoplasma; 1976 May 15; 23(4):421-6. PubMed ID: 794745
    [Abstract] [Full Text] [Related]

  • 13. Tumor regression after intralesional injection of mycobacterial components emulsified in 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (squalene), 2,6,10,15,19,23-hexamethyltetracosane (squalane), peanut oil, or mineral oil.
    Yarkoni E, Rapp HJ.
    Cancer Res; 1979 May 15; 39(5):1518-20. PubMed ID: 427795
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with nonviable microbial components.
    Ribi E, Milner KC, Granger DL, Kelly MT, Yamamoto K, Brehmer W, Parker R, Smith RF, Strain SM.
    Ann N Y Acad Sci; 1976 May 15; 277(00):228-38. PubMed ID: 187099
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy with an intralesionally administered synthetic cord factor analogue.
    Yarkoni E, Rapp HJ, Polonsky J, Lederer E.
    Int J Cancer; 1978 Nov 15; 22(5):564-9. PubMed ID: 721317
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6'-dimycolate) and synthetic analogues.
    Pimm MV, Baldwin RW, Polonsky J, Lederer E.
    Int J Cancer; 1979 Dec 15; 24(6):780-5. PubMed ID: 544531
    [Abstract] [Full Text] [Related]

  • 17. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.
    McLaughlin CA, Schwartzman SM, Horner BL, Jones GH, Moffatt JG, Nestor JJ, Tegg D.
    Science; 1980 Apr 25; 208(4442):415-6. PubMed ID: 7189295
    [Abstract] [Full Text] [Related]

  • 18. Interstitial and hemorrhagic pneumonitis induced by mycobacterial trehalose dimycolate.
    Seggev J, Goren MB, Carr RI, Kirkpatrick CH.
    Am J Pathol; 1982 Mar 25; 106(3):348-55. PubMed ID: 6801989
    [Abstract] [Full Text] [Related]

  • 19. In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guérin is due principally to trehalose mycolates.
    Geisel RE, Sakamoto K, Russell DG, Rhoades ER.
    J Immunol; 2005 Apr 15; 174(8):5007-15. PubMed ID: 15814731
    [Abstract] [Full Text] [Related]

  • 20. Interferon-gamma independent formation of pulmonary granuloma in mice by injections with trehalose dimycolate (cord factor), lipoarabinomannan and phosphatidylinositol mannosides isolated from Mycobacterium tuberculosis.
    Takimoto H, Maruyama H, Shimada KI, Yakabe R, Yano I, Kumazawa Y.
    Clin Exp Immunol; 2006 Apr 15; 144(1):134-41. PubMed ID: 16542375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.